ReviewThe Journal of allergy and clinical immunology2010
What targeting eosinophils has taught us about their role in diseases.
Review in The Journal of allergy and clinical immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 110 citations in OpenAlex.
- The eosinophil surface receptor epidermal growth factor-like module containing mucin-like hormone receptor 1 (EMR1): a novel therapeutic target for eosinophilic disorders.The Journal of allergy and clinical immunology · 2014Trial
- Spatial Eosinophil Phenotypes as Immunopathogenic Determinants in Inflammatory Diseases.Cells · 2025Review
- Effect of Long-Term Tai Chi Therapy on the Immune-Inflammatory Pathway in Patients with Schizophrenia with Antipsychotic-Stabilized.Molecular neurobiology · 2025Article
- Eosinophils: A Friend or Foe in Human Health and Diseases.Kidney diseases (Basel, Switzerland) · 2023Review
- Article
- Lessons learned from targeting eosinophils in human disease.Seminars in immunopathology · 2021Review
- Eosinophils and eosinophil-associated disorders: immunological, clinical, and molecular complexity.Seminars in immunopathology · 2021Review
- Effects of Deacetylasperulosidic Acid on Atopic Dermatitis through Modulating Immune Balance and Skin Barrier Function in HaCaT, HMC-1, and EOL-1 Cells.Molecules (Basel, Switzerland) · 2021Article
- Interleukin-5 in the Pathophysiology of Severe Asthma.Frontiers in physiology · 2019Review
- Diagnosis and Management of Eosinophilic Esophagitis.Immunology and allergy clinics of North America · 2018Review
- OK-432 Acts as Adjuvant to Modulate T Helper 2 Inflammatory Responses in a Murine Model of Asthma.Journal of immunology research · 2018Article
- Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.Drug design, development and therapy · 2017Review
- Is there a future for biologics in the management of chronic rhinosinusitis?International forum of allergy & rhinology · 2016Review
- Eosinophils, galectins, and a reason to breathe.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Measurement of Inflammation in Eosinophilic Esophagitis Using an Eosinophil Peroxidase Assay.The American journal of gastroenterology · 2016Article
- Eosinophilic Skin Diseases: A Comprehensive Review.Clinical reviews in allergy & immunology · 2016Review
- Novel Therapies for Eosinophilic Disorders.Immunology and allergy clinics of North America · 2015Review
- Eosinophils in mucosal immune responses.Mucosal immunology · 2015Review
- Endogenous airway mucins carry glycans that bind Siglec-F and induce eosinophil apoptosis.The Journal of allergy and clinical immunology · 2015Article
- Determinants of eosinophil survival and apoptotic cell death.Apoptosis : an international journal on programmed cell death · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Eosinophil-associated disease is a term used to encompass a range of disorders from hypereosinophilic syndrome to asthma. Despite the longstanding belief that eosinophils can be primary contributors to disease pathophysiology, it is only in recent years that direct and selective reduction or elimination of eosinophils can be achieved in animals or human subjects. These developments have been made possible in mice through clever targeting of eosinophil production. Antibodies and other agents that target soluble eosinophil-related molecules, such as IL-5, or cell-surface structures, such as CCR3, have also proved useful in reducing blood and tissue eosinophil counts. In human subjects the only eosinophil-selective agents tested in clinical trials thus far are neutralizing antibodies to IL-5, with promising but mixed results. At the very least, such forms of pharmacologic hypothesis testing of the role of eosinophils in certain airway, gastrointestinal, and hematologic diseases has finally provided us with new insights into disease pathogenesis. At its optimistic best, these and other targeted agents might someday become available for those afflicted with eosinophil-associated disorders. This review summarizes what has been learned in vivo in both preclinical and clinical studies of eosinophil-directed therapies, with an emphasis on recent advances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.